Biomarker: F014-IgE Soybean

Overview

F014-IgE Soybean measures immunoglobulin E (IgE) antibodies directed against soybean proteins in serum. IgE sensitization can indicate an immune response to soy, but it does not by itself establish clinical soy allergy or predict reaction severity. Higher concentrations may support suspected soy allergy when consistent symptoms occur after soy exposure, while low or undetectable concentrations reduce but do not completely exclude IgE-mediated allergy. The test is clinically useful for identifying soy as a possible trigger and for supporting follow-up assessment, but results require interpretation with the medical history, other allergy tests, and, when appropriate, a medically supervised oral food challenge.

Clinical Use Cases

Evaluation of suspected IgE-mediated soy allergy after compatible symptoms following soy exposure.
Identification of soy sensitization when skin-prick testing cannot be performed, including in patients taking antihistamines or with extensive dermatitis.
Assessment of soy as a potential trigger in selected children with persistent moderate-to-severe atopic dermatitis, particularly when there is a history of immediate food-related reactions.
Follow-up assessment of known or suspected childhood soy allergy, including evaluation of possible development of tolerance.
Research into soy allergy, soy-specific IgE concentrations, and component-resolved diagnostics.
Support for distinguishing sensitization from clinical allergy when interpreted alongside clinical history and oral food challenge results.

Specimen Types

Venous blood, typically collected as serum.
In clinical research, stored serum samples may also be analyzed for soybean-specific IgE and soy allergen components.

Measurement Methods

Immunoassay for serum soybean-specific IgE, commonly reported in kUA/L or a comparable standardized unit.
Fluorescence enzyme immunoassay or other automated allergen-specific IgE immunoassays.
Skin-prick testing with soybean extract as a complementary method, although this measures a skin wheal-and-flare response rather than serum F014-IgE.
Component-resolved immunoassays for soybean allergens such as Gly m 4, Gly m 5, Gly m 6, and Gly m 8 in specialized clinical or research settings.
Supervised oral food challenge for confirmation of clinical reactivity. This is not a measurement method for IgE, but it is the reference clinical procedure for confirming food allergy when indicated.

Test Preparation and Influencing Factors

Fasting is generally not required for a serum soybean-specific IgE test unless other tests collected at the same time require fasting.
Do not stop antihistamines or other medicines without instructions from the ordering clinician. Unlike skin-prick testing, serum-specific IgE testing can usually be performed while antihistamines are being taken.
A positive result indicates sensitization and may occur without symptoms after soy ingestion.
Cross-reactivity with related allergens, including birch-pollen-associated soy components, can affect interpretation and may contribute to clinically irrelevant positive or negative extract-based results.
Total IgE concentration, age, atopic dermatitis, other allergic diseases, and the patient’s clinical history can influence the predictive value of the result.
Soy-specific IgE concentration does not reliably predict reaction severity.
Results may change over time. Decreasing soybean-specific IgE may accompany development of tolerance in children, but repeat testing must be interpreted with the clinical history.
Assay platforms, allergen extracts, reporting units, and decision thresholds may differ between laboratories. Results should be interpreted using the reference information provided by the testing laboratory.
Oral food challenges and elimination or reintroduction procedures should be conducted only under appropriate clinical supervision when there is a risk of a significant reaction.